Novo Nordisk announced it will cut the U.S. list prices for Ozempic and Wegovy by up to 50 percent, bringing both drugs to approximately $675 per month effective January 2027 [1]. The move represents the most significant pricing concession yet from the Danish pharmaceutical giant, which has faced mounting political and public pressure over the cost of its blockbuster GLP-1 drugs.

The company also committed to a faster timeline for Medicare patients. Starting mid-2026, Medicare beneficiaries will be able to access Wegovy for obesity treatment at roughly $274 per month through negotiated formulary arrangements, well before the broader list-price reduction takes effect [2].

The current list price for Wegovy exceeds $1,300 per month, putting it beyond reach for millions of uninsured and underinsured Americans even as clinical demand has surged. Ozempic, approved for type 2 diabetes, carries a similar sticker price that has drawn Congressional scrutiny.

Novo's announcement follows a year of intense lobbying from patient advocacy groups and bipartisan pressure in Washington, where the affordability of weight-loss drugs has become a surprisingly unifying issue. The company framed the cuts as part of a broader commitment to access, though critics noted the January 2027 effective date leaves nine months of full-price prescriptions on the table.

For the estimated 40 percent of American adults who qualify as obese, the announcement represents progress measured in months, not miracles. The drugs work. The question has always been who can afford them.

-- NORA WHITFIELD, New York